Literature DB >> 12971623

Establishment and characterization of a human uterine endometrial undifferentiated carcinoma cell line, TMG-L.

Kiyoshi Hasegawa1, Machiko Suzuki, Kunimi Ishikawa, Akira Yasue, Rina Kato, Azumi Nakamura, Jun Kuroki, Yasuhiro Udagawa.   

Abstract

A new cell line of human uterine endometrial undifferentiated carcinoma, designated as TMG-L, was established from the metastatic lymph node of 56-year-old patient TMG-L cells have been cultured with Ham's F-12 medium supplemented with 10% FCS and grew as a loosely adherent monolayer with polygonal or spindle-shaped cells exhibiting poor cell-cell contact and piled up against each other, showing a tendency to grow as floating cells. The doubling time of this cell line was about 48 hours, and chromosomal analysis revealed aneuploidy at passage 25. The cells formed tumors in SCID mouse, the histology of which was similar to that of undifferentiated carcinoma component of primary tumor. TMG-L cells showed the loss of expression and membranous localization of either E-cadherin or alpha-catenin, implied corresponding loss of their adhesive function. And this dysfunction implicated the biological aggressive behavior of uterine endometrial undifferentiated carcinoma. This cell line appears to provide a useful system for studying uterine undifferentiated carcinoma in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971623     DOI: 10.1111/j.1749-0774.2003.tb00126.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  21 in total

1.  E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.

Authors:  Kevin Holcomb; Roberto Delatorre; Bader Pedemonte; Carla McLeod; Lisa Anderson; Joseph Chambers
Journal:  Obstet Gynecol       Date:  2002-12       Impact factor: 7.661

2.  p53 mutations and expression in ovarian cancers: correlation with overall survival.

Authors:  W H Wen; A Reles; I B Runnebaum; J Sullivan-Halley; L Bernstein; L A Jones; J C Felix; R Kreienberg; A el-Naggar; M F Press
Journal:  Int J Gynecol Pathol       Date:  1999-01       Impact factor: 2.762

3.  [Experimental studies on the cell adhesion molecule E-cadherin and in vitro invasion of endometrial carcinoma cell lines].

Authors:  N Okamura; Y Mori; T Endo; E Ito; R Kudo
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1996-05

4.  Tumors in Iceland. 12. Malignant tumours of the corpus of the uterus. A histological classification, epidemiological considerations and survival.

Authors:  K R Benediktsdóttir; J G Jónasson; J Hallgrímsson
Journal:  APMIS       Date:  1989-09       Impact factor: 3.205

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases.

Authors:  V M Abeler; K E Kjørstad; J M Nesland
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

7.  Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma.

Authors:  T Fujioka; Y Takebayashi; T Kihana; Y Kusanagi; K Hamada; H Ochi; T Uchida; M Fukumoto; M Ito
Journal:  Oncol Rep       Date:  2001 Mar-Apr       Impact factor: 3.906

8.  Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy.

Authors:  S J Robboy; R Bradley
Journal:  Obstet Gynecol       Date:  1979-09       Impact factor: 7.661

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis.

Authors:  M Saegusa; M Hashimura; T Yoshida; I Okayasu
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.